Zentalis Pharmaceuticals, Inc.

NasdaqGM:ZNTL Voorraadrapport

Marktkapitalisatie: US$236.1m

Zentalis Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

De winst van Zentalis Pharmaceuticals zal naar verwachting dalen met 3% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 34.1% per jaar. De winst per aandeel zal naar verwachting groeien met 5.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -128.4% zijn.

Belangrijke informatie

-3.0%

Groei van de winst

5.4%

Groei van de winst per aandeel

Biotechs winstgroei27.3%
Inkomstengroei34.1%
Toekomstig rendement op eigen vermogen-128.4%
Dekking van analisten

Good

Laatst bijgewerkt18 Oct 2024

Recente toekomstige groei-updates

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

May 09
Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

Recent updates

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully

Oct 03
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully

Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher

Jun 19
Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Jun 13
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

May 09
Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

Apr 12

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Feb 29
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Zentalis: Leading WEE1 Developer After AstraZeneca's Exit

Feb 05

Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?

Jan 09
Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?

We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

Oct 13
We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Jun 30
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Dec 01
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer

Sep 27

Zentalis Pharmaceuticals has a new chief medical officer

Sep 19

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Aug 17
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

May 02
Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Jan 12
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Oct 14
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jul 02
Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Mar 08
Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jan 20
Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Winst- en omzetgroeiprognoses

NasdaqGM:ZNTL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202620-297-305-2689
12/31/2025N/A-286-273-2339
12/31/202441-212-204-18911
6/30/202441-195-167-166N/A
3/31/202441-219-211-211N/A
12/31/2023N/A-292-208-208N/A
9/30/2023N/A-286-205-205N/A
6/30/2023N/A-285-201-199N/A
3/31/2023N/A-241-165-163N/A
12/31/2022N/A-237-166-164N/A
9/30/2022N/A-232-168-163N/A
6/30/2022N/A-182-169-164N/A
3/31/2022N/A-168-173-167N/A
12/31/2021N/A-159-160-154N/A
9/30/2021N/A-149-149-144N/A
6/30/2021N/A-179-133-132N/A
3/31/2021N/A-152-109-107N/A
12/31/2020N/A-118-88-87N/A
9/30/2020N/A-92-73-73N/A
6/30/2020N/A-70-62-62N/A
3/31/2020N/A-53-47-47N/A
12/31/2019N/A-46-39-39N/A
12/31/20180-23-24-24N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ZNTL de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ZNTL de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ZNTL de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van ZNTL ( 34.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van ZNTL ( 34.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat ZNTL binnen 3 jaar verliesgevend zal zijn.


Ontdek groeibedrijven